Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker XENE
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 28, 2026 | Christopher John Kenney Chief Medical Officer | XENE Xenon Pharmaceuticals Inc. | Sale | 700 | $60.98 | $42.7K Sale | Form 4 ↗ |
| Aug 28, 2026 | Christopher John Kenney Chief Medical Officer | XENE Xenon Pharmaceuticals Inc. | Sale | 6,368 | $60.17 | $383.2K Sale | Form 4 ↗ |
| Aug 11, 2026 | Steven Gannon Director | XENE Xenon Pharmaceuticals Inc. | Sale | 10,000 | $64.06 | $640.6K Sale | Form 4 ↗ |
| Jun 5, 2026 | Gary Patou Director | XENE Xenon Pharmaceuticals Inc. | Sale | 1,322 | $53.14 | $70.3K Sale | Form 4 ↗ |
| Jun 5, 2026 | Gillian Cannon Director | XENE Xenon Pharmaceuticals Inc. | Sale | 1,190 | $53.14 | $63.2K Sale | Form 4 ↗ |
| Mar 13, 2026 | Christopher John Kenney Chief Medical Officer | XENE Xenon Pharmaceuticals Inc. | Sale | 1,410 | $55.23 | $77.9K Sale | Form 4 ↗ |
| Mar 13, 2026 | Andrea DiFabio Chief Legal Officer | XENE Xenon Pharmaceuticals Inc. | Sale | 1,342 | $55.23 | $74.1K Sale | Form 4 ↗ |
| Mar 13, 2026 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 7,308 | $55.23 | $403.6K Sale | Form 4 ↗ |
| Mar 10, 2026 | Christopher John Kenney Chief Medical Officer | XENE Xenon Pharmaceuticals Inc. | Sale | 2,771 | $60.11 | $166.6K Sale | Form 4 ↗ |
| Mar 10, 2026 | Andrea DiFabio Chief Legal Officer | XENE Xenon Pharmaceuticals Inc. | Sale | 2,607 | $60.11 | $156.7K Sale | Form 4 ↗ |
| Mar 10, 2026 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 11,269 | $60.11 | $677.4K Sale | Form 4 ↗ |
| Mar 9, 2026 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 65,000 | $62.06 | $4.0M Sale | Form 4 ↗ |
| Mar 9, 2026 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 61,652 | $60.08 | $3.7M Sale | Form 4 ↗ |
| Mar 9, 2026 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 43,348 | $59.26 | $2.6M Sale | Form 4 ↗ |
| Mar 9, 2026 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 2,449 | $61.26 | $150.0K Sale | Form 4 ↗ |
| Mar 9, 2026 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 10,072 | $60.47 | $609.1K Sale | Form 4 ↗ |
| Mar 9, 2026 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 12,479 | $59.50 | $742.5K Sale | Form 4 ↗ |
| Mar 9, 2026 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 21,515 | $60.49 | $1.3M Sale | Form 4 ↗ |
| Mar 9, 2026 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 31,694 | $59.88 | $1.9M Sale | Form 4 ↗ |
| Mar 9, 2026 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 21,791 | $58.81 | $1.3M Sale | Form 4 ↗ |
| Jan 2, 2026 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 2,062 | $44.93 | $92.6K Sale | Form 4 ↗ |
| Jan 2, 2026 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 37,938 | $44.40 | $1.7M Sale | Form 4 ↗ |
| Dec 8, 2025 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 2,010 | $46.32 | $93.1K Sale | Form 4 ↗ |
| Dec 8, 2025 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 8,820 | $45.59 | $402.1K Sale | Form 4 ↗ |
| Dec 5, 2025 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 14,375 | $45.03 | $647.3K Sale | Form 4 ↗ |
| Nov 28, 2025 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 97 | $45.01 | $4,366 Sale | Form 4 ↗ |
| Oct 1, 2025 | Ian Mortimer PRESIDENT, CEO & INTERIM CFO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 25,000 | $40.16 | $1.0M Sale | Form 4 ↗ |
| Jun 5, 2025 | Steven Gannon Director | XENE Xenon Pharmaceuticals Inc. | Sale | 3 | $30.48 | $91.44 Sale | Form 4 ↗ |
| Jan 27, 2025 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 1,149 | $41.07 | $47.2K Sale | Form 4 ↗ |
| Jan 27, 2025 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 15,166 | $40.46 | $613.6K Sale | Form 4 ↗ |
| Jan 24, 2025 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 22,468 | $40.20 | $903.2K Sale | Form 4 ↗ |
| Jan 23, 2025 | Ian Mortimer PRESIDENT & CEO, Director | XENE Xenon Pharmaceuticals Inc. | Sale | 16,217 | $40.08 | $650.0K Sale | Form 4 ↗ |
| Dec 18, 2024 | Sherry Aulin Chief Financial Officer | XENE Xenon Pharmaceuticals Inc. | Sale | 11,510 | $41.19 | $474.1K Sale | Form 4 ↗ |
| Dec 18, 2024 | Sherry Aulin Chief Financial Officer | XENE Xenon Pharmaceuticals Inc. | Sale | 7,199 | $41.23 | $296.8K Sale | Form 4 ↗ |
| Nov 22, 2024 | Gary Patou Director | XENE Xenon Pharmaceuticals Inc. | Sale | 2,040 | $41.05 | $83.7K Sale | Form 4 ↗ |
| Nov 22, 2024 | Gary Patou Director | XENE Xenon Pharmaceuticals Inc. | Sale | 2,851 | $41.11 | $117.2K Sale | Form 4 ↗ |
36 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:14 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances